ANALISIS RASIONALITAS FARMAKOTERAPI PASCA Percutaneous Coronary Intervention (PCI) PADA PASIEN PENYAKIT JANTUNG KORONER DENGAN STENT KORONER DI RUMAH SAKIT DAERAH SAMARINDA

Abstract

Coronary Heart Disease (CHD) is one of the most prevalent cardiovascular diseases and a leading cause of mortality both in Indonesia and globally. The standard interventional approach for CHD patients involves stent implantation through Percutaneous Coronary Intervention (PCI). Following this procedure, patients require long-term pharmacotherapy to prevent restenosis and other cardiovascular complications. Non-adherence to clinical guidelines in medication use may increase the risk of adverse effects and diminish therapeutic outcomes, thereby necessitating an evaluation of treatment rationality. This study aimed to evaluate patient characteristics, medication patterns, and pharmacotherapy rationality in CHD patients with coronary stents at a Regional Hospital in Samarinda. A descriptive retrospective study was conducted using medical records from January to December 2023. A total of 81 patients met the inclusion criteria and were analyzed using four rationality parameters established by the Indonesian Ministry of Health: appropriateness of indication, drug selection, dosage, and patient. The results demonstrated that the majority of patients were male and of adult age (18-59 years). The most frequently prescribed regimen was the combination of ticagrelor with aspirin and clopidogrel with aspirin as dual antiplatelet therapy (DAPT), followed by statin administration and medications for comorbidities including diabetes mellitus and hypertension. The rationality analysis revealed 100% appropriateness for indication, dosage, and patient parameters, while drug selection appropriateness reached 97.5%.